Reference

Compare peptides

Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.

Compound 1

Compound 2

Compound 3 (optional)

Compound 4 (optional)

No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.

Link to this comparison: /compare?peptides=ru58841,retatrutide,cagrilintide

Side-by-side comparison of RU58841, Retatrutide, Cagrilintide
Identity
	RU58841	Retatrutide	Cagrilintide
Class	Nonsteroidal arylhydantoin androgen-receptor antagonist, studied as a topical solution and supplied as a research chemical	Investigational triple agonist of GIP, GLP-1 and glucagon receptors	Investigational long-acting acylated amylin analogue
Also listed as	RU 58841, RU-58841, PSK-3841, HMR-3841	LY3437943, LY-3437943	Not recorded
Molecular formula	C17H18F3N3O3	Not recorded	C194H312N54O59S2
Molecular weight	369.34 g/mol	4731.33 g/mol (average mass, widely cited for the free base)	4409 g/mol
CAS	154992-24-2	2381089-83-2	1415456-99-3
PubChem CID	132981	Not recorded	171397054
Sequence length	Not recorded	Not recorded	Described structurally, not as a residue list
Data caveat	PSK-3841 and HMR-3841 refer to the same molecule. Full caveat	PubChem’s retatrutide record states a CID is not available as a discrete structure. Full caveat	None recorded
United States regulatory status
Status	No FDA-approved product	Investigational	Investigational
FDA application	None recorded	None recorded	None recorded
Compounding	No FDA compounding entry recorded	No FDA compounding entry recorded	No FDA compounding entry recorded
WADA	Not named in this record	Not named in this record	Not named in this record
Research profile
Research purpose	Topical androgen-receptor blockade (unpublished trials)	Triple-agonist metabolic research	No plain-English profile recorded
Proposed mechanism	Binds the androgen receptor and was designed as a rapidly metabolised topical drug to limit systemic exposure. A 2026 human study detected parent drug in blood after a topical dose, so the local-only assumption needs qualification.	Proposed triple agonism: GLP-1 and GIP effects on appetite and insulin, plus glucagon-receptor signalling in the liver and energy expenditure. The net clinical contribution of each arm is still being studied.	No plain-English profile recorded
Human evidence	Two completed human trials registered under PSK-3841 in the early 2000s, with no published results. A 2026 study in six men characterised metabolism and systemic exposure.	A published 48-week Phase 2 trial in 338 adults, plus Phase 3 trials registered and sponsor topline disclosures. No approved product exists.	No plain-English profile recorded
Evidence tier	Phase 2 trials registered or reported	Phase 3 trials registered or reported	No plain-English profile recorded
Known safety concerns	Systemic exposure has been demonstrated after topical administration. No published human safety dataset from the completed trials is available. Research-chemical supply is not pharmaceutical-grade; identity, purity and sterility are not guaranteed by an approval.	Gastrointestinal adverse effects were reported in the Phase 2 trial. Resting heart rate increased transiently in the Phase 2 trial. The full Phase 3 safety database and any regulatory review are not public as an approved label.	No plain-English profile recorded
Evidence gaps	Any published efficacy result from the completed trials. A human safety dataset and long-term outcomes. Whether the demonstrated systemic exposure has meaningful hormonal effects. Independent quality standards for commercially supplied material.	Peer-reviewed Phase 3 results, including full adverse-event tables. Long-term cardiovascular and lean-mass outcomes. Any regulatory decision.	No plain-English profile recorded
Head-to-head evidence	No published head-to-head trial against finasteride or any other hair-loss treatment.	No published head-to-head trial against semaglutide or tirzepatide. Cross-trial comparisons are not head-to-head evidence.	No plain-English profile recorded
Named pathways	Androgen receptor · DHT signalling · Follicular miniaturisation	GIP receptor · GLP-1 receptor · Glucagon receptor · Hepatic lipid oxidation · Energy expenditure	No plain-English profile recorded
Evidence on file
Records	3Open evidence file	2Open evidence file	0Open evidence file
Human-interventional records	3	2	0
Human-observational records	0	0	0
Animal records	0	0	0
In-vitro records	0	0	0
Reviews	0	0	0
Regulatory documents	0	0	0
Earliest indexed	2005	2023	Not recorded
Latest indexed	2026	2026	Not recorded

Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.